Adcetris Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) designed to target CD30, a protein present on the surface of certain cancer cells, including those associated with Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines a monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE), enabling targeted chemotherapy delivery to cancer cells, enhancing efficacy while minimizing off-target side effects.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary forms of adcetris are powder and liquid. It is provided as a sterile, white to off-white lyophilized powder in single-dose vials. Before administration, healthcare providers reconstitute the powder with a specified amount of sterile water to prepare it for intravenous infusion. Its indications include Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, and others. Adcetris is utilized in various settings, such as hospitals, drug stores, and more.

The adcetris market research report is one of a series of new reports from The Business Research Company that provides adcetris market statistics, including adcetris industry global market size, regional shares, competitors with a adcetris market share, detailed adcetris market segments, market trends, and opportunities, and any further data you may need to thrive in the adcetris industry. This adcetris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adcetris market size is expected to see strong growth in the next few years. It will grow to $1,954.7 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to rising investment in oncology research, increasing demand for precision medicine, expansion into emerging markets, growing focus on patient access programs, ongoing clinical trials for expanded indications. Major trends in the forecast period include increasing adoption of targeted therapies in oncology, expansion into new indications for CD30-positive malignancies, growth in healthcare spending and access in emerging markets, advancements in antibody-drug conjugate technologies, increasing demand for personalized cancer treatments.

The increasing prevalence of cancer is projected to drive the growth of the adcetris market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer cases is largely attributed to lifestyle factors, such as poor diet and physical inactivity, increased exposure to environmental pollutants, and advancements in diagnostic methods. Adcetris provides substantial benefits for cancer patients by specifically targeting and binding to CD30-positive cancer cells, delivering potent cytotoxic agents directly to the tumor, improving treatment effectiveness, minimizing systemic side effects, and presenting a promising treatment option for patients with certain types of Hodgkin lymphoma and other CD30-expressing cancers. For example, in January 2023, the American Cancer Society reported that the number of cancer cases in the United States reached 1,958,310, with 609,820 cancer-related deaths. As a result, the growing incidence of cancer is a key factor driving the adcetris market.

A prominent trend in the adcetris market is the focus on developing enhanced antibody-drug conjugates (ADCs) and improved drug delivery systems, including combination therapies. These strategies aim to improve therapeutic efficacy, minimize side effects, and more precisely target cancer cells. Combination therapies involve using two or more therapeutic agents with different mechanisms of action, often in synergy, to boost efficacy, reduce resistance, and enhance patient outcomes, while potentially lowering adverse effects compared to monotherapy. For instance, in October 2023, Takeda Pharmaceutical Company received approval from the European Commission (EC) for the use of ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for treating adults with previously untreated CD30+ Stage III Hodgkin lymphoma. This ADC targets CD30, a key marker in Hodgkin lymphoma. The trial results showed that combining ADCETRIS with AVD significantly improved both modified progression-free survival and overall survival rates compared to standard treatments.

In January 2024, Pfizer Inc. acquired Seagen Inc. for $43 billion. This acquisition aims to strengthen Pfizer's oncology portfolio by incorporating Seagen's innovative ADCs, including Adcetris, to enhance its cancer treatment offerings. The move is designed to drive growth in targeted therapies and accelerate Pfizer's ability to deliver advanced cancer treatments to patients worldwide. Seagen Inc. is a US-based biotechnology firm that markets Adcetris.

Major players operating in the adcetris market are Takeda Pharmaceutical Company Limited; Seagen Inc.

North America was the largest region in the adcetris market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adcetris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adcetris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adcetris market consists of sales of brentuximab vedotin-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors for the treatment of lymphoma and related cancers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adcetris Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adcetris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adcetris ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adcetris market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Powder; Liquid
• 2) By Indication: Hodgkin Lymphoma; Systemic Anaplastic Large Cell Lymphoma; Cutaneous T-Cell Lymphoma; Other Indication
• 3) By Application: Hospital; Drugs Store; Other Applications
• Companies Mentioned: Takeda Pharmaceutical Company Limited; Seagen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.